Our data are consistent with the hypotheses: (a) that hyperglycaemia during organ donation occurs as a consequence of beta‐cell death; (b) that beta‐cell death predicts adverse outcomes in islet transplantation; and (c) that our clinical study findings1, 4 relating the donor insulin use to adverse transplant outcomes are explained by beta‐cell death. The gene discussed is INS; the disease is Hyperglycemia.